Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Veracyte Inc (NASDAQ: VCYT) closed the day trading at $43.05 down -0.92% from the previous closing price of $43.45. In other words, the price has decreased by -$0.92 from its previous closing price. On the day, 0.6 million shares were traded. VCYT stock price reached its highest trading level at $44.59 during the session, while it also had its lowest trading level at $42.655.
Ratios:
For a better understanding of VCYT, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.29 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 34.65. For the most recent quarter (mrq), Quick Ratio is recorded 5.94 and its Current Ratio is at 6.23. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
On October 20, 2025, Canaccord Genuity started tracking the stock assigning a Hold rating and target price of $40.
On March 20, 2025, Craig Hallum started tracking the stock assigning a Buy rating and target price of $45.Craig Hallum initiated its Buy rating on March 20, 2025, with a $45 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 16 ’25 when McGuire Annie sold 10,739 shares for $43.13 per share. The transaction valued at 463,204 led to the insider holds 67,760 shares of the business.
ANN MCGUIRE bought 10,739 shares of VCYT for $467,469 on Dec 16 ’25. On Dec 05 ’25, another insider, EASTHAM KARIN, who serves as the Director of the company, sold 20,000 shares for $45.45 each. As a result, the insider received 908,923 and left with 13,554 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VCYT now has a Market Capitalization of 3403066880 and an Enterprise Value of 3077091840. As of this moment, Veracyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 113.38, and their Forward P/E ratio for the next fiscal year is 26.76. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.34. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.87 while its Price-to-Book (P/B) ratio in mrq is 2.71. Its current Enterprise Value per Revenue stands at 6.215 whereas that against EBITDA is 41.753.
Stock Price History:
The Beta on a monthly basis for VCYT is 1.92, which has changed by 0.04146695 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, VCYT has reached a high of $50.71, while it has fallen to a 52-week low of $22.61. The 50-Day Moving Average of the stock is 0.17%, while the 200-Day Moving Average is calculated to be 30.05%.
Shares Statistics:
Over the past 3-months, VCYT traded about 893.61K shares per day on average, while over the past 10 days, VCYT traded about 713310 shares per day. A total of 79.03M shares are outstanding, with a floating share count of 77.34M. Insiders hold about 2.16% of the company’s shares, while institutions hold 110.75% stake in the company. Shares short for VCYT as of 1767139200 were 4990310 with a Short Ratio of 5.58, compared to 1764288000 on 5707781. Therefore, it implies a Short% of Shares Outstanding of 4990310 and a Short% of Float of 7.04.
Earnings Estimates
. The current rating of Veracyte Inc (VCYT) reflects the combined expertise of 10.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.33, with high estimates of $0.42 and low estimates of $0.27.
Analysts are recommending an EPS of between $1.67 and $1.6 for the fiscal current year, implying an average EPS of $1.64. EPS for the following year is $1.59, with 10.0 analysts recommending between $2.0 and $1.21.
Revenue Estimates
8 analysts predict $131.94M in revenue. The current quarter. It ranges from a high estimate of $133M to a low estimate of $131M. As of. The current estimate, Veracyte Inc’s year-ago sales were $118.63MFor the next quarter, 8 analysts are estimating revenue of $130.81M. There is a high estimate of $133.7M for the next quarter, whereas the lowest estimate is $127M.
A total of 9 analysts have provided revenue estimates for VCYT’s current fiscal year. The highest revenue estimate was $509.8M, while the lowest revenue estimate was $507.5M, resulting in an average revenue estimate of $508.52M. In the same quarter a year ago, actual revenue was $445.76MBased on 10 analysts’ estimates, the company’s revenue will be $567.23M in the next fiscal year. The high estimate is $581M and the low estimate is $560M.
